阿宾登健康交易下跌 10.0%

Abingdon Health Plc（伦敦证券交易所代码：ABDX – 获取免费报告）的股价周四下跌 6.7%。该股最低交易价格为 GBX 9.53（0.12 美元），最后交易价格为 GBX 10.03（0.13 美元）。

LONDON (MarketWatch) — Shares of Abingdon Health Plc (ABDX) fell sharply Thursday after the rapid-test maker said it’s in talks with potential partners for a licensing deal for its Covid-19 lateral flow test in the U.S.

伦敦（MarketWatch）——周四，Abingdon Health Plc (ABDX) 股价大幅下跌，此前这家快速检测制造商表示正在与潜在合作伙伴就其在美国的 Covid-19 侧流检测的许可协议进行谈判

Abingdon shares were recently down 10%, among the worst performers in the FTSE All-Share Index (FTAS) , which was up 0.3%. The stock traded as low as 9.53 pence ($0.12) and last traded at 10.03 pence ($0.13).

Abingdon 股价最近下跌 10%，是富时全股指数 (FTAS) 中表现最差的股票之一，该指数上涨了 0.3%。该股交易价格低至 9.53 便士（0.12 美元），最新交易价格为 10.03 便士（0.13 美元）。

The company said it’s had “positive initial discussions” with potential partners, and that it now plans to begin formal negotiations for a licensing deal for the test in the U.S.

该公司表示，已与潜在合作伙伴进行了“积极的初步讨论”，现在计划开始就在美国进行测试的许可协议进行正式谈判

The talks come after Abingdon said in March that it had received emergency-use authorization from the Food and Drug Administration for its Covid-19 lateral flow test, which can detect the virus in 15 minutes. The test is already available in the U.K.

会谈之前，Abingdon 在 3 月份表示，其 Covid-19 侧流检测已获得美国食品和药物管理局的紧急使用授权，该检测可在 15 分钟内检测出病毒。该测试已在英国推出

Abingdon said Thursday that it also continues to be in discussions with potential partners for licensing deals in other territories.

阿宾登周四表示，它还在继续与潜在合作伙伴讨论其他地区的许可交易。

The company added that it’s also working on developing a new lateral flow test for the Omicron variant of Covid-19, which is expected to be available in the second half of 2022.

该公司补充说，它还在致力于为 Covid-19 的 Omicron 变体开发一种新的侧向层析测试，预计将于 2022 年下半年推出。

Abingdon shares have now lost 86% of their value over the past year, as demand for Covid-19 tests has waned and the company has struggled to find new licensing partners for its products.

由于对 Covid-19 测试的需求减弱以及该公司一直在努力为其产品寻找新的许可合作伙伴，Abingdon 的股价在过去一年中已经损失了 86%。